Quest Diagnostics Incorporated : Poised for Long-Term Growth

Presented by:

Jim Davis

CEO and President

January 11, 2023

Safe harbor disclosure

The statements in the following presentations that are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and that reflect management's current estimates, projections, expectations, or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response; adverse results from pending or future government investigations, lawsuits, or private actions; the competitive environment; the complexity of billing, reimbursement, and revenue recognition for clinical laboratory testing; changes in government regulations; changing relationships with customers, payers, suppliers, or strategic partners; and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

2

What you'll hear today

Quest's essential		Key drivers to		Enhancing		Disciplined
role as the leader		accelerate		operational		capital
in diagnostic		growth		excellence		deployment
information
services

3

Quest Diagnostics is the leader in Diagnostic Information Services at the center of healthcare

Leader in rapidly evolving market with unsurpassed focus, scale, and innovation

Serves

~50%

of US hospitals and physicians

Serves 1/3 of the US adult population

and ~50%

within 3 years

>60B

patient data points

7,100+

retail and patient access points

~24,000

phlebotomists,

paramedics, and health and wellness professionals

~2M

tests processed per day

~$9.8B ESTIMATED 2022 REVENUES

All amounts as of 12/31/2021, except for revenues

4

Experienced, results-driven executive leadership team

Jim Davis

CEO &

President

Sam Samad

EVP

Chief Financial

Officer

Gabrielle

Wolfson

SVP

Chief Information

and Digital Officer

Cecilia

McKenney

SVP

Chief Human

Resources Officer

5

Cathy Doherty

SVP

Regional

Businesses

Patrick

Plewman

SVP

Diagnostic

Services

Mike Prevoznik

SVP

General Counsel

Karthik Kuppusamy

SVP

Clinical Solutions

Mark Delaney

SVP

Chief

Commercial

Officer

Gary Samuels

SVP

Chief

Communications

Officer

Mark Gardner

SVP

Molecular

Genomics and

Oncology

Jay Wohlgemuth, MD

SVP

R&D, Medical and CMO

Kristin Wallace

SVP

Chief Compliance Officer

Dermot

Shorten

SVP

Strategy, M&A and Ventures

Richard

Adams

VP/GM

Consumer- Initiated Testing